Hou Z, Lu Y, Zhang B, Rahman A, Zhao Y, Xi N
Molecules. 2023; 28(13).
PMID: 37446696
PMC: 10343301.
DOI: 10.3390/molecules28135035.
Sanchez-Diez M, Alegria-Aravena N, Lopez-Montes M, Quiroz-Troncoso J, Gonzalez-Martos R, Menendez-Rey A
Biomedicines. 2022; 10(5).
PMID: 35625820
PMC: 9139065.
DOI: 10.3390/biomedicines10051083.
Mazumder K, Aktar A, Roy P, Biswas B, Hossain M, Sarkar K
Molecules. 2022; 27(9).
PMID: 35566385
PMC: 9102595.
DOI: 10.3390/molecules27093036.
Shih Y, Peng C, Chiang P, Shieh M
Pharmaceutics. 2022; 14(4).
PMID: 35456602
PMC: 9030189.
DOI: 10.3390/pharmaceutics14040768.
Zhang Y, Li Y, Sun C, Chen X, Han L, Wang T
Cancers (Basel). 2021; 13(16).
PMID: 34439157
PMC: 8391236.
DOI: 10.3390/cancers13164002.
Hydroxycamptothecin Inhibits Peritendinous Adhesion the Endoplasmic Reticulum Stress-Dependent Apoptosis.
Yao Z, Wang W, Ning J, Zhang X, Zheng W, Qian Y
Front Pharmacol. 2019; 10:967.
PMID: 31551777
PMC: 6737834.
DOI: 10.3389/fphar.2019.00967.
One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion.
Sun X, Zhu D, Cai Y, Shi G, Gao M, Zheng M
Int J Nanomedicine. 2019; 14:2115-2126.
PMID: 30988612
PMC: 6440449.
DOI: 10.2147/IJN.S193783.
Binding Performance of Human Intravenous Immunoglobulin and 20()-7-Ethylcamptothecin.
Liu Y, Li Y, Yao X, Qi H, Wei X, Liu J
Molecules. 2018; 23(9).
PMID: 30231526
PMC: 6225142.
DOI: 10.3390/molecules23092389.
Structure-Based Drug Design and Identification of HO-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo.
Pan P, Chen J, Li X, Li M, Yu H, Zhao J
J Med Chem. 2018; 61(19):8613-8624.
PMID: 30227711
PMC: 6668024.
DOI: 10.1021/acs.jmedchem.8b00498.
Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?.
Li F, Jiang T, Li Q, Ling X
Am J Cancer Res. 2018; 7(12):2350-2394.
PMID: 29312794
PMC: 5752681.
iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.
Ma L, Chen Q, Ma P, Han M, Xu Z, Kang Y
Nanomedicine (Lond). 2017; 12(16):1991-2006.
PMID: 28745123
PMC: 5551526.
DOI: 10.2217/nnm-2017-0107.
Study of the Binding between Camptothecin Analogs and FTO by Spectroscopy and Molecular Docking.
Ren T, Wang Z, Zhang L, Wang N, Han X, Wang R
J Fluoresc. 2017; 27(4):1467-1477.
PMID: 28401412
DOI: 10.1007/s10895-017-2086-2.
Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?.
Li F, Ling X, Harris D, Liao J, Wang Y, Westover D
Am J Cancer Res. 2017; 7(2):370-382.
PMID: 28337384
PMC: 5336509.
Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.
Vesela E, Chroma K, Turi Z, Mistrik M
Biomolecules. 2017; 7(1).
PMID: 28230817
PMC: 5372731.
DOI: 10.3390/biom7010019.
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.
Coriat R, Faivre S, Mir O, Dreyer C, Ropert S, Bouattour M
Int J Nanomedicine. 2016; 11:6207-6216.
PMID: 27920527
PMC: 5123727.
DOI: 10.2147/IJN.S110274.
An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett R, Stewart R, Hogan P, Ptak R, Mankowski M, Hartman T
Antiviral Res. 2016; 136:51-59.
PMID: 27825797
PMC: 5125868.
DOI: 10.1016/j.antiviral.2016.11.001.
Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).
Lv P, Elsayed M, Agama K, Marchand C, Pommier Y, Cushman M
J Med Chem. 2016; 59(10):4890-9.
PMID: 27097152
PMC: 5317102.
DOI: 10.1021/acs.jmedchem.6b00220.
Fabrication and optimization of camptothecin loaded Eudragit S 100 nanoparticles by Taguchi L4 orthogonal array design.
Mahalingam M, Krishnamoorthy K
Int J Pharm Investig. 2015; 5(3):147-54.
PMID: 26258056
PMC: 4522864.
DOI: 10.4103/2230-973X.160852.
CFS-1686 causes cell cycle arrest at intra-S phase by interference of interaction of topoisomerase 1 with DNA.
Lin R, Yang C, Ku S, Ho C, Huang S, Yang M
PLoS One. 2014; 9(12):e113832.
PMID: 25460368
PMC: 4252032.
DOI: 10.1371/journal.pone.0113832.
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.
Lv P, Agama K, Marchand C, Pommier Y, Cushman M
J Med Chem. 2014; 57(10):4324-36.
PMID: 24800942
PMC: 4033654.
DOI: 10.1021/jm500294a.